Related Experiment Videos
Perspectives on anti-HER monoclonal antibodies
Malcolm Ranson1, Mark X Sliwkowski
1Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK. malcolm.ransom@man.ac.uk
Abstract:
The ability of Herceptin to prolong survival in women with HER2-overexpressing breast tumors has proven the concept of using humanized or chimeric monoclonal antibodies (MAbs) for cancer therapy. MAbs have been developed that are specific for many tumorigenic molecules and receptors. They can potentially be used to treat a range of solid tumors. Among the most promising targets for therapy are members of the human epidermal growth factor receptor (HER/ErbB) family, particularly HER1 and HER2. Several MAbs have been produced that are directed against HER1. One of these agents, cetuximab (Erbitux), is now advanced in clinical development. HER2 is also a key target and methods are being investigated to maximize the effect of using MAbs to inhibit this receptor. One approach aims to augment the efficacy of trastuzumab (Herceptin) by coupling it to a chemotherapeutic agent, thus enabling the delivery of cytotoxic therapy at a cellular level. Another opportunity is based on research that shows that HER2 acts as a dimerization partner for other HER receptors and consequently is important in HER-ligand-dependent tumor growth. Therefore, anti-HER2 MAbs that inhibit the association of HER2 with other HER family members have the potential to be highly effective. This article reviews some of these alternative approaches to MAb-based anti-HER therapy that will hopefully improve treatment outcome for patients with a range of solid tumors.
Insights
Monoclonal antibodies (MAbs) show promise for cancer therapy, particularly targeting HER1 and HER2 receptors. Research explores enhancing MAb efficacy through drug conjugation and inhibiting receptor dimerization for improved solid tumor treatment.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Humanized or chimeric monoclonal antibodies (MAbs) have demonstrated success in cancer therapy, exemplified by Herceptin for HER2-overexpressing breast cancer.
- The human epidermal growth factor receptor (HER/ErbB) family, specifically HER1 and HER2, represents a critical target for MAb-based cancer therapeutics.
- Existing therapies like cetuximab (Erbitux) target HER1, while strategies to enhance HER2-targeted treatments are under investigation.
Purpose of the Study:
- To review alternative approaches for MAb-based anti-HER therapy.
- To explore methods for augmenting the efficacy of HER2-targeted MAbs.
- To discuss strategies aimed at improving treatment outcomes for solid tumors.
Main Methods:
- Review of current research on monoclonal antibodies (MAbs) targeting HER1 and HER2.
- Investigation of strategies to enhance MAb efficacy, including drug conjugation and inhibition of receptor dimerization.
- Analysis of HER2's role as a dimerization partner in HER-ligand-dependent tumor growth.
Main Results:
- Monoclonal antibodies (MAbs) targeting HER1, such as cetuximab, are in advanced clinical development.
- Strategies to enhance trastuzumab (Herceptin) efficacy include coupling it with chemotherapeutic agents for targeted cytotoxic delivery.
- Inhibiting the association of HER2 with other HER family members via MAbs shows potential for effective anti-cancer therapy.
Conclusions:
- MAb-based therapies targeting HER1 and HER2 offer significant potential for treating various solid tumors.
- Novel approaches, including drug conjugation and disruption of receptor dimerization, are being explored to maximize MAb effectiveness.
- These advanced MAb strategies hold promise for improving patient outcomes in cancer treatment.